A Study on Recurrent Gastrointestinal Stromal Tumor

[1]  T. Hwang,et al.  Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment , 2010, Journal of surgical oncology.

[2]  J. Blay,et al.  Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: Results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment: A French Sarcoma Group Study. , 2010 .

[3]  B. Druker,et al.  Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.

[4]  H. Chang,et al.  Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs) , 2008, Journal of surgical oncology.

[5]  G. Demetri,et al.  Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Antonescu,et al.  Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation , 2005, Clinical Cancer Research.

[7]  P. Nyckowski,et al.  Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate , 2006, Journal of surgical oncology.

[8]  R. DeMatteo,et al.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. , 2000, Annals of surgery.

[9]  C. Mussi,et al.  Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Jonathan J. Lewis,et al.  Salvage surgery for patients with recurrent gastrointestinal sarcoma , 2000, Cancer.

[11]  Angela Greco,et al.  A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. , 2004, Gastroenterology.

[12]  Wei Zhang,et al.  A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal Tumors , 2004, Cancer Research.